Compare WRLD & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WRLD | IVA |
|---|---|---|
| Founded | 1962 | 2011 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 813.0M | 737.1M |
| IPO Year | 1994 | 2020 |
| Metric | WRLD | IVA |
|---|---|---|
| Price | $161.81 | $3.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $15.20 |
| AVG Volume (30 Days) | 29.1K | ★ 2.9M |
| Earning Date | 10-23-2026 | 09-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.33 | N/A |
| Revenue | ★ $585,166,700.00 | N/A |
| Revenue This Year | $4.84 | N/A |
| Revenue Next Year | $6.82 | N/A |
| P/E Ratio | $127.33 | ★ N/A |
| Revenue Growth | ★ 3.60 | N/A |
| 52 Week Low | $110.00 | $2.82 |
| 52 Week High | $227.68 | $7.98 |
| Indicator | WRLD | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 36.01 | 56.06 |
| Support Level | $125.84 | $3.23 |
| Resistance Level | $168.09 | $3.76 |
| Average True Range (ATR) | 5.71 | 0.24 |
| MACD | -0.37 | 0.10 |
| Stochastic Oscillator | 24.50 | 93.62 |
World Acceptance Corp operates a small-loan consumer finance (installment loan) business. It offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. The Company generally serves individuals with limited access to other sources of consumer credit such as banks, credit unions, other consumer finance businesses and credit card lenders. The Company also offers income tax return preparation services to its loan customers and other individuals. The traditional installment loan industry is a fragmented segment of the consumer lending industry. The Company has one reportable segment: the consumer finance segment.
Inventiva SA is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with unmet medical needs.